A multi-targeted approach to suppress tumor-promoting inflammation.

Autor: Samadi AK; Sanus Biosciences, San Diego, CA, United States., Bilsland A; Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, UK., Georgakilas AG; Physics Department, School of Applied Mathematics and Physical Sciences, National Technical University of Athens, Athens, Greece., Amedei A; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy., Amin A; Department of Biology, College of Science, United Arab Emirates University, Al Ain, United Arab Emirates; Faculty of Science, Cairo University, Cairo, Egypt., Bishayee A; Department of Pharmaceutical Sciences, College of Pharmacy, Larkin Health Sciences Institute, Miami, FL, United States., Azmi AS; Department of Pathology, Wayne State Univeristy, Karmanos Cancer Center, Detroit, MI, USA., Lokeshwar BL; Department of Urology, University of Miami, Miller School of Medicine, Miami, FL, United States; Miami Veterans Administration Medical Center, Miami, FL, United States., Grue B; Department of Environmental Science, Dalhousie University, Halifax, Nova Scotia, Canada; Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada., Panis C; Laboratory of Inflammatory Mediators, State University of West Paraná, UNIOESTE, Paraná, Brazil., Boosani CS; Department of BioMedical Sciences, School of Medicine, Creighton University, Omaha, NE, United States., Poudyal D; Department of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC, United States., Stafforini DM; Huntsman Cancer Institute and Department of Internal Medicine, University of Utah, Salt Lake City, UT, United States., Bhakta D; School of Chemical and Biotechnology, SASTRA University, Thanjavur, Tamil Nadu, India., Niccolai E; University of Florence, Florence, Italy., Guha G; School of Chemical and Biotechnology, SASTRA University, Thanjavur, Tamil Nadu, India., Vasantha Rupasinghe HP; Department of Environmental Sciences, Faculty of Agriculture and Department of Pathology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada., Fujii H; Department of Orthopedic Surgery, Nara Medical University, Kashihara, Nara, Japan., Honoki K; Department of Orthopedic Surgery, Nara Medical University, Kashihara, Nara, Japan., Mehta K; Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Aquilano K; Department of Biology, University of Rome 'Tor Vergata', Rome, Italy., Lowe L; Getting to Know Cancer, Truro, Nova Scotia, Canada. Electronic address: leroy.lowe@gettingtoknowcancer.org., Hofseth LJ; Department of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC, United States., Ricciardiello L; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy., Ciriolo MR; Department of Biology, University of Rome 'Tor Vergata', Rome, Italy., Singh N; Advanced Molecular Science Research Centre (Centre for Advanced Research), King George's Medical University, Lucknow, Uttar Pradesh, India., Whelan RL; Department of Surgery, St. Luke's Roosevelt Hospital, New York, NY, United States., Chaturvedi R; School of Biotechnology, Jawaharlal Nehru University, New Delhi, India., Ashraf SS; Department of Chemistry, College of Science, United Arab Emirates University, Al Ain, United Arab Emirates., Shantha Kumara HMC; Department of Surgery, St. Luke's Roosevelt Hospital, New York, NY, United States., Nowsheen S; Medical Scientist Training Program, Mayo Graduate School, Mayo Medical School, Mayo Clinic, Rochester, MN, United States., Mohammed SI; Department of Comparative Pathobiology, Purdue University Center for Cancer Research, West Lafayette, IN, United States., Keith WN; Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, UK., Helferich WG; University of Illinois at Urbana Champaign, Champaign, IL, United States., Yang X; University of Illinois at Urbana Champaign, Champaign, IL, United States.
Jazyk: angličtina
Zdroj: Seminars in cancer biology [Semin Cancer Biol] 2015 Dec; Vol. 35 Suppl, pp. S151-S184. Date of Electronic Publication: 2015 May 05.
DOI: 10.1016/j.semcancer.2015.03.006
Abstrakt: Cancers harbor significant genetic heterogeneity and patterns of relapse following many therapies are due to evolved resistance to treatment. While efforts have been made to combine targeted therapies, significant levels of toxicity have stymied efforts to effectively treat cancer with multi-drug combinations using currently approved therapeutics. We discuss the relationship between tumor-promoting inflammation and cancer as part of a larger effort to develop a broad-spectrum therapeutic approach aimed at a wide range of targets to address this heterogeneity. Specifically, macrophage migration inhibitory factor, cyclooxygenase-2, transcription factor nuclear factor-κB, tumor necrosis factor alpha, inducible nitric oxide synthase, protein kinase B, and CXC chemokines are reviewed as important antiinflammatory targets while curcumin, resveratrol, epigallocatechin gallate, genistein, lycopene, and anthocyanins are reviewed as low-cost, low toxicity means by which these targets might all be reached simultaneously. Future translational work will need to assess the resulting synergies of rationally designed antiinflammatory mixtures (employing low-toxicity constituents), and then combine this with similar approaches targeting the most important pathways across the range of cancer hallmark phenotypes.
(Copyright © 2015 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: